EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
暂无分享,去创建一个
S. Gabriel | M. Meyerson | W. Sellers | Jeffrey C. Lee | P. Jänne | H. Greulich | H. Sasaki | F. Kaye | T. Boggon | M. Eck | N. Lindeman | J. Paez | Y. Fujii | P. Herman | K. Naoki | B. Johnson | Sean I Tracy
[1] 刘金明,et al. IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW,Thompson RW,et al//Proc Natl Acad Sci U S A , 2005 .
[2] C. Streuli. Faculty Opinions recommendation of EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. , 2004 .
[3] Daniel Jones. Anticancer drugs: To the rescue? , 2004, Nature Reviews Drug Discovery.
[4] Thomas J Lynch,et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. , 2004, Lung cancer.
[5] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[6] M. Kuwano,et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. , 2004, Molecular cancer therapeutics.
[7] William Pao,et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] G. Giaccone,et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Roy S Herbst,et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] C. Sawyers. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. , 2003, Genes & development.
[11] A. D. Van den Abbeele,et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] David Cella,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.
[13] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Giovanni Parmigiani,et al. Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers , 2003, Nature Reviews Cancer.
[15] M. Loda,et al. Sensitivity of Non-Small-Cell Lung Cancer Cell Lines Established from Patients Treated with Prolonged Infusions of Paclitaxel , 2003, Oncology.
[16] M. Meyerson,et al. Missense mutations of the BRAF gene in human lung adenocarcinoma. , 2002, Cancer research.
[17] M. Sliwkowski,et al. Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.
[18] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[19] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[20] J. Kuriyan,et al. The Conformational Plasticity of Protein Kinases , 2002, Cell.
[21] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[22] C. Sawyers,et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.
[23] B. Freidlin,et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Ennis,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[25] E. Dmitrovsky,et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. , 1993, Cancer research.
[26] Chris Williams. Oncology , 1990, The Lancet.
[27] M. Shibuya,et al. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors , 1988, Molecular and cellular biology.
[28] A. Jemal,et al. Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.
[29] H. Hansen,et al. Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.
[30] THE AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE AND CONVOCATION WEEK. , 1904, Science.